Akèy › Feokromositòm
Etid klinik pou Feokromositòm ap rekrite nan Etazini
16 etid pou Feokromositòm ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Washington, DC9 etid
- Baltimore, MD3 etid
- Los Angeles, CA3 etid
- Nashville, TN3 etid
- Chicago, IL3 etid
- Cedar Rapids, IA3 etid
- Philadelphia, PA3 etid
Pa eta
- Illinois3 etid
- Iowa3 etid
- Kalifòni3 etid
- Maryland10 etid
- Michigan3 etid
- Pennsylvania3 etid
- Tennessee4 etid
- Texas3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Sep 29, 2026 · NCT06479811Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04924075Diagnosis of Pheochromocytoma
Ap rekriteFaz 1
Laj 3 a 120 · Tout sèks · Mizajou Sep 22, 2026 · NCT00004847Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Aug 25, 2026 · NCT03206060Project: Every Child for Younger Patients With Cancer
Ap rekriteEtid obsèvasyon
Jiska laj 25 · Tout sèks · Mizajou Aug 25, 2026 · NCT02402244Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT00001238Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
Ap rekriteFaz 1/2
Laj 18 a 120 · Tout sèks · Mizajou Aug 18, 2026 · NCT06427798Using the EHR to Advance Genomic Medicine Across a Diverse Health System
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT06377033Familial Investigations of Childhood Cancer Predisposition
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jun 17, 2026 · NCT03050268A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Jun 15, 2026 · NCT06041516Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Ap rekriteFaz 2
Laj 1 ak plis · Tout sèks · Mizajou May 29, 2026 · NCT0010728918F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Ap rekriteFaz 2
Laj 18 a 120 · Tout sèks · Mizajou May 19, 2026 · NCT06503146Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Ap rekriteFaz 1/2
Laj 18 a 90 · Tout sèks · Mizajou May 14, 2026 · NCT05636618Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Mar 17, 2026 · NCT04119024In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Feb 27, 2026 · NCT05636540Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Tout laj · Tout sèks · Mizajou Oct 15, 2025 · NCT03160274Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.